Royalty Pharma (RPRX) Equity Average (2019 - 2026)

Royalty Pharma has disclosed Equity Average across 8 years of filings, most recently posting $9.8 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $9.8 billion, down 2.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 billion (down 2.33% YoY), and the FY2025 annual result was $10.0 billion, down 1.81% from the prior year.
• Equity Average came in at $9.8 billion for Q1 2026 at Royalty Pharma, up from $9.7 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $10.4 billion in Q3 2022 to a low of $9.6 billion in Q3 2025.
• The 5-year median for Equity Average is $9.8 billion (2023), against an average of $9.9 billion.
• Across the five-year window, Equity Average declined 6.85% in 2023 and gained 4.74% in 2024, its largest moves.
• Royalty Pharma's Equity Average stood at $10.0 billion in 2022, then dropped by 1.37% to $9.8 billion in 2023, then climbed by 4.74% to $10.3 billion in 2024, then fell by 6.14% to $9.7 billion in 2025, then climbed by 1.63% to $9.8 billion in 2026.
• The last three Equity Average figures came in at $9.8 billion (Q1 2026), $9.7 billion (Q4 2025), and $9.6 billion (Q3 2025), per Business Quant data.